Research Article
Cost-Effectiveness Analysis of Biomarker-Guided Treatment for Metastatic Gastric Cancer in the Second-Line Setting
Table 2
Summary of parameters for sensitivity analyses.
| | Parameter | Range (SD) | Distribution |
| | Proportion MSI-H | 0.02–0.22 (0.05) | Beta | | Probabilities | | Probability of disease progression (MSI-H: PEM) | ±30% | Uniform | | Probability of disease progression (all other strategies) | ±30% | Normal | | Probability of cancer mortality on 3L best supportive care | ±30% | Normal | | Costs (total) | | Pembrolizumab | $10831–$15331 ($1354) | Gamma | | Pembrolizumab trAEs (grade 3/4) | $14615–$24358 ($2436) | Gamma | | Paclitaxel | $1843–$2343 ($230) | Gamma | | Paclitaxel trAEs (grade 3/4) | $9898–$16497 ($1649) | Gamma | | Ramucirumab + paclitaxel | $11996–$16996 ($1500) | Gamma | | Ramucirumab + paclitaxel trAEs (grade 3/4) | $15493–$25822 ($2582) | Gamma | | Best supportive care | $4136–$6136 ($311) | Gamma | | Utilities/Disutilities | | 2L progression-free survival | 0.55–0.69 | Uniform | | 3L best supportive care following progression | 0.22–0.57 | Uniform | | Pembrolizumab trAEs (grade 1/2) | 0.02–0.14 | Uniform | | Pembrolizumab trAEs (grade 3/4) | 0.08–0.22 | Uniform | | Paclitaxel trAEs (grade 1/2) | 0.05–0.13 | Uniform | | Paclitaxel trAEs (grade 3/4) | 0.06–0.37 | Uniform | | Ramucirumab + paclitaxel trAEs (grade 1/2) | 0.00–0.24 | Uniform | | Ramucirumab + paclitaxel trAEs (grade 3/4) | 0.16–0.35 | Uniform |
|
|
